Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Apr 29;13(4):936-939.
doi: 10.21037/tlcr-24-100. Epub 2024 Apr 25.

Antibody-drug conjugate development: opening windows for EGFR-mutant EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancers?

Toyoaki Hida  1
Affiliations
Editorial

Antibody-drug conjugate development: opening windows for EGFR-mutant EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancers?

Toyoaki Hida. Transl Lung Cancer Res. .
No abstract available

Keywords: Antibody-drug conjugates (ADCs); EGFR-tyrosine kinase inhibitor resistance (EGFR-TKI resistance); MET gene alterations; biparatopic antibodies (biparatopic Abs); bystander effect.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-100/coif). T.H. serves as an unpaid editorial board member of Translational Lung Cancer Research from January 2024 to December 2025. And he received lecture fees from Daiichi Sankyo, AstraZeneca, and AbbVie. The author has no other conflicts of interest to declare.

Comment on

References

    1. Jain N, Smith SW, Ghone S, et al. Current ADC Linker Chemistry. Pharm Res 2015;32:3526-40. 10.1007/s11095-015-1657-7 - DOI - PMC - PubMed
    1. Beck A, Goetsch L, Dumontet C, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov 2017;16:315-37. 10.1038/nrd.2016.268 - DOI - PubMed
    1. Sun X, Ponte JF, Yoder NC, et al. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates. Bioconjug Chem 2017;28:1371-81. 10.1021/acs.bioconjchem.7b00062 - DOI - PubMed
    1. Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 2018;9:33-46. 10.1007/s13238-016-0323-0 - DOI - PMC - PubMed
    1. Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer 2017;117:1736-42. 10.1038/bjc.2017.367 - DOI - PMC - PubMed